Clinical Feasibility & Validation of the Virtual Reality GlenxRose Speech-Language Therapies

Sponsor
University of Alberta (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05695131
Collaborator
Alberta Health services (Other)
30
1
2
16
1.9

Study Details

Study Description

Brief Summary

Factors related to successful rehabilitation are often directly related to adherence; for instance, dosage, frequency, and intensity can burden the patient regarding time and motivational factors. Furthermore, surrounding salience, patients may lose interest or find an intervention boring after a few sessions. It is well documented that nonadherence not only impacts rehabilitation for the patient but can also further prolong treatment, and increase hospital and clinician costs, in addition to a higher prevalence of future comorbidities. Therefore, strategies that improve patient adherence can significantly help optimize patient care and treatment outcomes.

One avenue to increase patient adherence is through the gamification of rehabilitation therapies using virtual reality (VR). Gamification of rehabilitation therapy can make mass practice required in rehabilitation therapies seemingly fun and more personally engaging for the patient. Additionally, the immersive experience achieved through VR can further promote salience and be customizable to individual patient requirements. As VR systems are now highly portable and relatively simple to utilize, they can provide an excellent opportunity to continue rehabilitation practice on the home front. Overall, the VR gamification of rehabilitation may increase adherence by shifting patients' perspectives of therapy as tedious, boring, or a hassle, to a fun and engaging game that ultimately helps their recovery processes.

The GlenXRose VR-delivered speech-language therapies (Cognitive Projections Lab, University of Alberta) have been developed and piloted in collaboration with the Glenrose Rehabilitation Hospital with the overall goal of increasing patient adherence, treatment outcomes, and satisfaction with vocal therapy. The proposed studies are to investigate the feasibility of implementing this technology in routine clinical care (specific to voice disorders), obtaining clinician feedback, examining associated financial costs, and continuing to examine the effect of the GlenXRose VR speech-language therapies on patient adherence and clinical outcomes, compared to traditional clinical care.

Condition or Disease Intervention/Treatment Phase
  • Device: GlenXRose Virtual Reality Speech Therapies
N/A

Detailed Description

Nonadherence to Speech-Language rehabilitation can result in suboptimal vocal recovery or compensation methods while impacting the quality of life and further burdening the healthcare system. In addition to traditional face-to-face voice therapy, many patients are further given daily voice exercises to practice at home. It is estimated that 38-74% of patients are nonadherent to voice therapies (Ebersole et al., 2018); with such a large prevalence, opportunities to prevent and mitigate nonadherence to voice therapy can significantly promote clinical/functional outcomes. In a recent meta-analysis, it is reported that methods increasing adherence to speech-language rehabilitation further promote home practice (Bartlett et al., 2022). One identified method of promise includes technological approaches (Bartlett et al., 2022) such as the GlenXRose VR Speech-Language therapies (VR-SLP).

Purpose & Objective: The GlenXRose VR-SLP program, developed by the Cognitive Projections lab at the University of Alberta in collaboration with the Glenrose Rehabilitation Hospital, provides patients with gamified vocal exercises, therapies, and education delivered through immersive virtual reality. With the degree of VR portability, patients will be able to take the equipment home to facilitate at-home vocal practice.

The objective of these studies is to examine the feasibility of implementing the previously developed GlenXRose VR Speech Language therapies (VR-SLP) to routine clinical care delivered by Speech-Language Pathologists to patients with vocal cord disorders. The variables of patient adherence to treatment as well as preliminary effects on vocal measurements (Voice Handicapped Index - 10; Acoustic Analysis of Voice) will be explored.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Sequential Assignment
Intervention Model Description:
Study 1: Single-Subject Experimental Design Studies will be Implemented (A-B Design) Study 2: Feasibility randomized controlled trial (control and intervention groups)Study 1: Single-Subject Experimental Design Studies will be Implemented (A-B Design) Study 2: Feasibility randomized controlled trial (control and intervention groups)
Masking:
Single (Outcomes Assessor)
Masking Description:
The outcomes assessor will be masked to group allocation (VR-delivered therapy + standard care, or traditional standard care alone). Participants will be asked by a research assistant not to reveal details of the group allocation prior to assessments.
Primary Purpose:
Treatment
Official Title:
Clinical Implementation, Feasibility, & Validation of the Virtual Reality Delivered GlenxRose Speech-Language Therapies to Improve Patient Adherence and Treatment Outcomes
Anticipated Study Start Date :
Apr 1, 2023
Anticipated Primary Completion Date :
May 1, 2024
Anticipated Study Completion Date :
Jul 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Virtual Reality Delivered Therapy + Standard Clinical Care

The GlenXRose virtual reality therapies will be delivered to participants using a head-mounted device to allow vocal therapy and practice. Participants will also receive routine clinical care provided by speech-language pathologists.

Device: GlenXRose Virtual Reality Speech Therapies
Speech therapies for vocal cord disorders have been developed for virtual reality implementation. These include various games to interact with in a virtual environment while conducting rehabilitation therapy, in addition to educational visualizations

No Intervention: Standard Clinical Care

Participants will receive routine clinical care provided by speech-language pathologists.

Outcome Measures

Primary Outcome Measures

  1. Change in Frequency and Treatment Adherence Rates [Up to 12 Weeks]

    Reported Frequency of Rehabilitation Therapy

  2. Change in Generalization [Up to 12 Weeks]

    Self-reported time using voice production techniques

  3. Change in Compliance Rate [Up to 12 Weeks]

    Self-reported time (using a visual analog scale)

  4. Change in Voice Handicap Index - 10 [Up to 12 Weeks]

    Quantification of participant reported perspectives of voice impairment(s)

  5. Change in Acoustic Analysis of Voice [Up to 12 Weeks]

    Conducted by Registered Speech-Language Pathologists (as part of standard care)

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Adults receiving speech-language therapy at the Glenrose Rehabilitation Hospital (Edmonton, AB, Canada; Alberta Health Services)

  • Presence of a speech disorder

  • Proficiency in English

  • Able to provide signed informed consent to participate in the study

Exclusion Criteria:
  • Severe cognitive impairments and/or behavioural impairments

  • Communication disorders that impact comprehension of verbal commands and understanding of scale used in the study

  • Previous history of neurological or psychiatric disorder

  • Substance use disorders

Contacts and Locations

Locations

Site City State Country Postal Code
1 Glenrose Rehabilitation Hospital Edmonton Alberta Canada T5G 0B7

Sponsors and Collaborators

  • University of Alberta
  • Alberta Health services

Investigators

  • Principal Investigator: Adriana Rios Rincon, PhD, R.OT, University of Alberta
  • Study Chair: Antonio Miguel Cruz, DrSc, University of Alberta
  • Study Chair: James Raso, MASc, Glenrose Rehabilitation Hospital, Alberta Health Services

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
University of Alberta
ClinicalTrials.gov Identifier:
NCT05695131
Other Study ID Numbers:
  • Pro00126403
First Posted:
Jan 23, 2023
Last Update Posted:
Jan 23, 2023
Last Verified:
Dec 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by University of Alberta
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 23, 2023